Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 4/2011

01-04-2011 | Letter to the Editor

Effective and safe administration of tocilizumab to a patient with rheumatoid arthritis on haemodialysis

Authors: Masahiro Iwamoto, Sumiko Honma, Yasushi Asano, Seiji Minota

Published in: Rheumatology International | Issue 4/2011

Login to get access

Excerpt

Tocilizumab is a humanised monoclonal anti-interleukin 6 (IL-6) receptor antibody blocking IL-6 function. Its therapy improved activity of rheumatoid arthritis (RA) [1, 2]. Therefore, it was approved for the treatment in April 2008 in Japan. We describe a patient with RA and chronic renal failure on haemodialysis (HD) who treated with tocilizumab. …
Literature
1.
Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T, CHARISMA Study Group (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:2817–2829PubMedCrossRef
2.
Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Murata N, van der Heijde D, Kishimoto T (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66:1162–1167PubMedCrossRef
3.
Iwamoto M, Homma S, Asano Y, Minota S (2005) Administration of leflunomide to a patient with rheumatoid arthritis on haemodialysis. Scand J Rheumatol 34:410–411PubMedCrossRef
4.
Singh R, Cuchacovich R, Huang W, Espinoza LR (2002) Infliximab treatment in a patient with rheumatoid arthritis on hemodialysis. J Reumatol 29:636–637
5.
Sugioka Y, Inui K, Koike T (2008) Use of etanercept in a patient with rheumatoid arthritis on hemodialysis. Mod Rheumatol 18:293–295PubMedCrossRef
Metadata
Title
Effective and safe administration of tocilizumab to a patient with rheumatoid arthritis on haemodialysis
Authors
Masahiro Iwamoto
Sumiko Honma
Yasushi Asano
Seiji Minota
Publication date
01-04-2011
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 4/2011
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-010-1430-5

Other articles of this Issue 4/2011

Rheumatology International 4/2011 Go to the issue

Original Article

The effects of β-glucan isolated from Pleurotus ostreatus on methotrexate treatment in rats with adjuvant arthritis

Original Article

Vitamin D level: is it related to disease activity in inflammatory joint disease?

Original Article

Prevalence of insulin resistance and metabolic syndrome in patients with gouty arthritis

Original Article

The effects of PDL-Ig on collagen-induced arthritis

Case Report

Coexistent pyoderma gangrenosum and tibialis anterior myositis as presenting manifestations of Crohn’s disease: case report and review of the literature

Letter to the Editor

Successful treatment with very low-dose etanercept in a patient with etanercept-induced liver dysfunction
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits